Although it was previously thought that anti-CSF-1R therapeutic strategies only targeted M2-TAMs, the evidence demonstrating CSF-1R expression in cancer cells and its contribution to tumor growth makes this receptor an interesting target for therapy. The gene discussed is CSF1R; the disease is neoplasm.